Regen BioPharma Inc (RGBP)

[Goldstrike]

Just Google his name and you can see what he is presently involved in.

Sure, top Google result (Bloomberg) yields his Regen affiliation on top of his resume:

Dr. Thomas E. Ichim, Ph.D., also known as Tom, has been Senior Research Consultant at Regen BioPharma Inc since July 2, 2016. Dr. Ichim has been the President and Chief Scientific Officer at Medistem, Inc., since October 6, 2012. Dr. Ichim is a Co-founder of Batu Biologics, Inc. and has been its Chief Scientific Officer since December 21, 2015. Dr. Ichim is the founder of ToleroTech Inc., OncoMune LLC and MedVax Pharma Corp. He served as Director of Research and Chief Scientific Officer of Regen BioPharma Inc from June 15, 2012 to October 30, 2015. Dr. Ichim serves as the Chief Scientific Officer of bioRASI, LLC. Dr. Ichim has been the Chief Executive Officer of Medistem, Inc., since March 2008 and served as its Chief of Scientific Development since January 2007. He is a seasoned biotechnology entrepreneur with a track record of scientific excellence. Dr. Ichim served a variety of instrumental roles for companies operating in the area of biologics. He obtained numerous regulatory approvals for companies such as MarrowTech Pharma and served as a Program Director for the global CRO bioRASI, under which he led efforts to develop, clinically assess, and approve various stem cell and cellular therapies. He is an accomplished Scientist with 15 scientific papers published in areas ranging from immunological tolerance, to cancer therapy, to autoimmunity. He serves as a Director at Medistem, Inc. He serves as a Member of Advisory Board at Cromos Pharma,LLC. He serves as a Member of the Scientific Advisory Board at Orcrist Bio Inc., Entest, and MBVax Bioscience Inc. He is an ad-hoc editor and sits on several editorial boards. He has co-authored many scientific journal articles and is a peer reviewer for several scientific journals in the area of immunology and translational medicine. He is a member of Vendevia Group. He has been a Director of Therapeutic Solutions International, Inc. since January 22, 2016. He served as Director of Regen BioPharma Inc from July 15, 2013 to October 30, 2015. Dr. Ichim attended the University of Waterloo for his undergraduate training and graduate school at the University of Western Ontario, Canada. He holds a BSc in Biology from University of Waterloo, Waterloo, Ontario, Canada in 1998 and an MSc in Microbiology and Immunology from University of Western Ontario, London, Ontario, Canada in 2003. He also holds a Ph.D in Immunology from University of Sciences Arts and Technology, Olveston Monserrat in 2007

www.bloomberg.com/research/stocks/private/person.asp?personId=30991102&privcapId=205078445

Since Regen is at the top of the list, I can only assume that this position as Senior Research Consultant trumps all.